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Endothelin (ET-21) induced a sustained contraction of rat thoracic aortae (EC,, = 2.65 x 10-n’ M) in vitro, and caused 
a potent pressor effect in vivo after intravenous administration to rats. In contrast, the precursor deduced from porcine 
cDNA coding ET-21 (PET-39) had 1Wfold less contractile activity in vitro (EC,, = 3.26 x 1O-s M), and so did the pre- 
cursor from human cDNA (hET-38) (EC, = 1.48 x 108 M). However, both PET-39 and hET-38 caused almost the same 
dose-dependent pressor effects as ET-21 in vivo. After intravenous bolus injection at 1 nmol/kg, ET-21 caused an initial 
transient drop of the arterial pressure, and then induced a gradual pressor effect. On the other hand, hET-38 caused 
only a gradual rise of the arterial pressure. There may be different mechanism(s) for ET-21 and hET-38 which induce 
changes in the arterial pressure in vivo. 
Endothelin; Precursor; Arterial pressure; Vasoconstriction; (Rat aorta) 
1. INTRODUCTION 
Endothelin (ET-21), isolated from the cultures 
of porcine aortic endothelial cells, is a novel 
vasoconstrictor peptide consisting of 21 amino 
acid residues with two disulfide bonds [I]. It has 
been reported that ET-21 causes the contraction of 
various vessels such as porcine coronary artery [l] 
and rat aorta [2], and induces a pressor effect after 
intravenous administration to rats [l-3], 
Sequence analysis of porcine cDNA encoding 
ET-21 showed the existence of a 203-residue 
prepro-endothelin [l]. Based on the deduced 
amino acid sequence, Yanagisawa et al. [l] 
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of peptides for vasoconstrictor activity 
postulated a possible pathway for the production 
of mature ET-21. Thus, the dibasic-pair-specific 
endopeptidase, which processes the prepro-form 
of many other peptide hormones [4], may convert 
prepro-endothelin to the putative 39-amino acid 
residue precursor (pET-39). For the production of 
ET-21, PET-39 may be processed by a unique en- 
dopeptidase, named ‘endothelin converting en- 
zyme (ECE)’ . 
Recent analysis of human cDNA has shown that 
ET-21 is also present in human prepro-endothelin 
[5]. The dibasic-pair-specific endopeptidase may 
convert human prepro-endothelin to a putative 
38-amino acid residue precursor @ET-38: see 
fig. 1). 
It is of interest to know what role hET-38 and 
PET-39 may play during the maturation process of 
ET-21. The first approach to this problem is to 
look for the vasoconstrictor activity of hET-38 and 
PET-39. In this study, hET-38 and PET-39 were 
synthesized by the solid-phase method. The phar- 
macological activity of synthetic precursors was 
determined in vitro by measuring the contraction 
of rat thoracic aorta, and in vivo by recording the 
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Fig. 1. Schematic sequences of endothelin and its putative precursors. The sequence of PET-39 is illustrated. ET-21 is the N-terminal 
21-residue moiety of PET-39. The sequence of hET-38 is only illustrated where it differs from PET-39. The arrow indicates the putative 
site which may be cleaved by ECE. 
arterial pressure in anesthetized, chemically dener- 
vated rats. Both putative precursors (hET-38 and 
PET-39) have less vasoconstrictor activity in vitro 
than ET-21, but have a potent pressor effect in 
vivo comparable to ET-21. 
2. MATERIALS AND METHODS 
2.1. Synthesis of putative precursors of endothelin 
Synthetic ET-21 was purchased from Peptide Institute 
(Osaka, Japan). The other peptides were synthesized by the 
solid-phase method, using an automatic peptide synthesizer. 
Details of this synthesis will be described elsewhere. Obtained 
peptides were purified by a preparative reverse-phase HPLC. 
The purity and the position of two disulfide bridges of the syn- 
thesized products were estimated on an analytical reverse-phase 
HPLC. The amino acid sequence of synthesized peptides was 
confirmed using a gas-phase sequencer, followed by isocratic 
reverse-phase HPLC [6]. 
2.2. Measurement of the contraction of rat thoracic aortae 
The 3-mm long ring of endothelium-denuded thoracic aortae 
from male Wistar rats (250-300 g) was mounted in an organ 
bath filled with 10 ml of Krebs-Ringer solution (mM): 112 
NaCI, 4.7 KCl, 2.2 CaCls, 25 NaHCOs, 1.2 MgCls, 1.2 
KHrPOd, and 14 glucose. The tension of the ring connected 
with a transducer was measured isometrically. The 
concentration-response r lationship for ET-21, PET-39, and 
hET-38 was determined by means of cumulative administra- 
tion. The response of each aortic ring to the peptides was ex- 
pressed as a percent of its maximum response to K+ (40 mM). 
2.3. Measurement of the arterial pressure in rats 
Male Wistar rats (220-280 g) were anesthetized with 
urethane (1 g/kg, i.p.) and cr-chloralose (25 ,ug/kg, i.p.), and 
denervated with atropine (0.25 mg/kg, i.v.), propranolol 
(1 mg/kg, i.v.), and bunazosin (1 mg/kg, i.v.). The catheter 
connected with a pressure transducer was inserted into the right 
carotid artery for the measurement of blood pressure, and the 
catheter for drug administration was placed in the jugular vein. 
3. RESULTS AND DISCUSSION 
Fig.2 shows the concentration-response curves 
for the contractile activity of ET-21, hET-38, and 
PET-39. ET-21 caused strong contraction of the 
rat aortic ring (EC50 = 2.65 x lo-” M), as 
reported previously [I]. In contrast, the contractile 
potency of both hET-38 and PET-39 was less than 
that of ET-21 by approximately 2 orders of 
magnitude (fig.2), but was higher than that of the 
other vasoconstrictors, such as angiotensin II [7]. 
The EC50 values of hET-38 and PET-39 are 1.48 x 
10m8 M and 3.26 x 10e8 M, respectively. The max- 
imal tensions of the aortic ring at 3 x lo-’ M of 
hET-38 and PET-39 (125.9 + 3.2 and 132.8 + 
6.0%, respectively) were almost identical with that 
of ET-21 at 10e8 M (121.5 + 1.5%). Kimura et al. 
[8] have previously postulated that the removal of 
C-terminal Trp’r is the inactivation mechanism of 
ET-21. This removal reduced the potency of the 
contractile activity by 3 orders of magnitude, and 
led to the loss of the long-lasting activity. In our 
experiments, the putative precursors induced slow- 
and long-lasting contraction of rat aortic rings 
similarly to ET-21 (not shown). These results sup- 
port the hypothesis that conversion of the putative 
precursor to ET-21 is the activation process during 
biosynthesis of ET-21. 
Fig.3 shows the potency of the pressor effect in 
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Fig.2. Concentration-response curves for the contraction of rat 
aortic rings following cumulative administration of ET-21 (0, 
n = 8), hET-38 (O , n = 9) and PET-39 (A , n = 8). The data 
are given as means f SE. Stars indicate a significant difference 
between the activities of hET-38 and PET-39 @ < 0.01). 
rats after cumulative administration of ET-21, 
hET-38, and PET-39. ET-21 caused a dose- 
dependent elevation of the arterial pressure (fig.3). 
The half effective dose of ET-21 could not be 
calculated, because administration of ET-21 to the 
animals at doses higher than 3 nmol/kg caused 
death. Takasaki et al. [9] indicated that there were 
functional and structural similarities between 
ET-21 and sarafotoxin S6 (snake venom toxin). 
ET-21 may have the properties of an endogenous 
toxin. 
As shown in fig.3, hET-38 caused almost the 
same dose-dependent pressor effect in vivo as 
ET-21. The MBP value increased after administra- 
tion of doses higher than 0.1 nmol/kg. At doses 
higher than 3 nmol/kg, hET-38 also caused death. 
The effect of PET-39 in vivo was also similar to 
that of hET-38 (fig.3), but its potency was 
somewhat less than that of hET-38. At a dose of 
1.0 nmol/kg, the rise in MBP for PET-39 was 
significantly less than that for hET-38. The con- 
strictor activity in vitro of PET-39 was also 
significantly smaller than that of hET-38 at con- 
centrations of lo-’ M and 3 x lo-’ M (fig.2). Our 
preliminary experiments indicate that PET-39 is 
more sensitive to nonspecific proteases when com- 
I I I 
0.01 0.1 1 
Dose tnmol/Kg) 
I 
Fig.3. Dose-response curves for the arterial pressure following 
cumulative administration to rats of ET-21 (0, n = 5), hET-38 
(0 , n = 5) and PET-39 (A , n = 9). The data are expressed as 
a percent of the basal level of MBP and given as means f SE. 
The number of rats which survived at a dose of 3 nmol/kg is 
presented in parentheses. The star indicates a significant 
difference between the activities of hET-38 and PET-39 @ c 
0.01). 
pared with hET-38. It is possible that the lesser ac- 
tivity of PET-39 may be due to the higher 
sensitivity to the proteases. 
Although ET-21 may be the most active form 
converted from the precursor, the potency of the 
precursors in vivo was almost the same. In order to 
check the difference between the pressor effects of 
ET-21 and hET-38, the time-dependent effects on 
the arterial pressure of rat after the bolus ad- 
ministration (1 nmol/kg i.v.) were observed. As 
shown in fig.4, the response to ET-21 was 
biphasic, as described previously [l-3,10]. The in- 
itial effect of ET-21 was a transient drop of the 
arterial pressure within the first minute. The 
average of MBP at 0.5 min for 5 rats (45.6 +- 
3.0 mmHg) was much smaller than the basal level 
(62.4 + 5.1 mmHg). This effect may be due to 
vasodilation caused by the release of eicosanoids 
and/or endothelium-derived relaxing factor 
(EDRF) from endothelial cells, as described by De 
Nucci et al. [lo]. Then, ET-21 produced a prolong- 
ed pressor effect lasting for over 1 h. Heart rate 
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Fig.4. A typical chart of the arterial pressure following administration of ET-21 (A) and hET-38 (B) at a dose of 1 nmol/kg (i.v. bolus), 
to an anesthetized, chemically denervated rat. Arrows show the time of administration. BP, blood pressure (mmHg); MBP, mean 
blood pressure (mmHg); HR. heart rate (beats/mitt). 
was slightly increased by ET-21, but the magnitude 
of this increase was varied in each experiment. 
On the other hand, the effect of hET-38 was dif- 
ferent from that of ET-21 (fig.4). There was no in- 
itial drop in blood pressure, although hET-38 
causes a sustained rise in blood pressure lasting for 
over 1 h similar to ET-21. Even at 0.5 min the 
average of MBP for 4 rats (65.5 f 5.4 mmHg) was 
higher than the basal level (60.8 f 5.1 mmHg). 
This finding indicates that the mechanism(s) that 
induce changes in the arterial pressure is (are) dif- 
ferent for ET-21 and hET-38. The response of 
PET-39 was similar to that of hET-38 (not shown). 
Considering the finding that ET-21 caused an in- 
itial drop in blood pressure caused by the release of 
eicoaanoids and/or EDRF, it is likely that hET-38 
does cause the release of eicosanoids and/or 
EDRF. The other possibility is that hET-38 may be 
gradually converted to ET-21 at the site of activa- 
tion in vivo, and that the amounts of precursors 
converted to ET-21 were not be enough to cause a 
drop in blood pressure but may only cause a 
pressor effect. It is necessary to make clear the 
mechanisms of activation of endothelin in vivo, 
because this process may play an important role in 
the regulation of blood pressure. 
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